Alimera Sciences Company Leadership
| ALIM Stock | USD 3.55 0.03 0.84% |
Alimera Sciences' insiders are aggressively buying. The analysis of insiders' sentiment of trading Alimera Sciences stock suggests that most insiders are extremely bullish at this time. Alimera Sciences employs about 154 people. The company is managed by 23 executives with a total tenure of roughly 177 years, averaging almost 7.0 years of service per executive, having 6.7 employees per reported executive.
| Daniel Myers CEO President CEO, Director |
Alimera Sciences' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2023-09-14 | Caligan Partners Lp | Acquired 579000 @ 3.39 | View | ||
| 2023-05-17 | Adam Morgan | Acquired 1401901 @ 1.7 | View |
Monitoring Alimera Sciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Alimera |
Alimera Sciences' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Alimera Sciences' future performance. Based on our forecasts, it is anticipated that Alimera will maintain a workforce of about 150 employees by May 2024.Alimera Sciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.0123) % which means that it has lost $0.0123 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5876) %, meaning that it created substantial loss on money invested by shareholders. Alimera Sciences' management efficiency ratios could be used to measure how well Alimera Sciences manages its routine affairs as well as how well it operates its assets and liabilities. As of the 18th of April 2024, Return On Tangible Assets is likely to drop to -0.38. In addition to that, Return On Capital Employed is likely to drop to -0.01. At this time, Alimera Sciences' Asset Turnover is very stable compared to the past year.As of the 18th of April 2024, Common Stock Shares Outstanding is likely to grow to about 26.8 M, while Net Loss is likely to drop (5.3 M).
Alimera Sciences Workforce Comparison
Alimera Sciences is rated third in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 1,406. Alimera Sciences retains roughly 154 in number of employees claiming about 11% of equities under Health Care industry.
Alimera Sciences Profit Margins
The company has Profit Margin (PM) of (0.25) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.03 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.03.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.63 | 0.7575 |
|
|
Alimera Sciences Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Alimera Sciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Alimera Sciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Alimera Sciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-03-01 | 1.0 | 1 | 1 | 75,000 | 2,938 |
| 2023-09-01 | 1.6 | 8 | 5 | 28,890,257 | 16,948,377 |
| 2023-06-01 | 4.0 | 4 | 1 | 1,417,939 | 2,057,143 |
| 2023-03-01 | 5.3333 | 16 | 3 | 532,902 | 803,808 |
| 2022-03-01 | 4.0 | 8 | 2 | 230,000 | 251,175 |
| 2021-06-01 | 1.5 | 3 | 2 | 1,421 | 45.00 |
| 2021-03-01 | 3.3333 | 10 | 3 | 180,000 | 5,632 |
| 2020-03-01 | 1.0 | 10 | 10 | 154,086 | 12,902 |
| 2019-06-01 | 4.0 | 8 | 2 | 304,133 | 225,000 |
| 2019-03-01 | 0.381 | 8 | 21 | 1,600,400 | 248,757 |
| 2018-03-01 | 0.8095 | 17 | 21 | 1,721,800 | 257,831 |
| 2017-03-01 | 10.0 | 10 | 1 | 1,584,900 | 21,172 |
| 2016-12-01 | 0.5714 | 4 | 7 | 127,326 | 242,994 |
| 2016-09-01 | 0.5 | 1 | 2 | 51,471 | 102,942 |
| 2016-06-01 | 1.4 | 7 | 5 | 140,000 | 478,673 |
| 2015-12-01 | 6.2857 | 44 | 7 | 1,544,725 | 164,706 |
| 2015-09-01 | 0.5556 | 5 | 9 | 16,655 | 40,932 |
| 2015-06-01 | 0.8125 | 13 | 16 | 149,968 | 86,168 |
| 2015-03-01 | 1.0 | 7 | 7 | 1,185,000 | 22,500 |
| 2014-12-01 | 0.6923 | 9 | 13 | 34,431 | 135,091 |
| 2014-09-01 | 0.2727 | 6 | 22 | 2,634,819 | 2,916,636 |
| 2014-06-01 | 0.5833 | 14 | 24 | 183,945 | 244,469 |
| 2014-03-01 | 0.3333 | 5 | 15 | 94,226 | 490,932 |
| 2013-06-01 | 0.381 | 8 | 21 | 160,000 | 311,788 |
| 2012-12-01 | 1.75 | 14 | 8 | 1,330,047 | 4,523,942 |
| 2012-09-01 | 0.8571 | 6 | 7 | 76,797 | 34,818 |
| 2011-12-01 | 0.25 | 2 | 8 | 5,348 | 1,005,331 |
| 2011-09-01 | 1.5 | 6 | 4 | 51,640 | 563,795 |
| 2011-06-01 | 1.0 | 17 | 17 | 201,406 | 5,139,834 |
| 2011-03-01 | 1.6667 | 5 | 3 | 92,747 | 110,294 |
| 2010-06-01 | 0.7103 | 76 | 107 | 57,257,868 | 39,985,575 |
Alimera Sciences Notable Stakeholders
An Alimera Sciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Alimera Sciences often face trade-offs trying to please all of them. Alimera Sciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Alimera Sciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| David Holland | Co-Founder and Sr. VP of Sales and Marketing | Profile | |
| Daniel Myers | President CEO, Director | Profile | |
| Todd Wood | President Operations | Profile | |
| David Burke | Vice President | Profile | |
| Rich Cockrell | President | Profile | |
| Phil Jones | CFO | Profile | |
| Elliot CPA | CFO Treasurer | Profile | |
| Richard Eiswirth | Pres and CFO | Profile | |
| Kenneth Green | Chief Scientific Officer and Sr. VP | Profile | |
| John Snisarenko | Director | Profile | |
| James Largent | Independent Director | Profile | |
| Peter Pizzo | Independent Director | Profile | |
| Calvin Roberts | Independent Director | Profile | |
| Mary Szela | Director | Profile | |
| Garheng Kong | Independent Director | Profile | |
| Brian Halak | Independent Director | Profile | |
| Mark Brooks | Independent Director | Profile | |
| Christopher Visick | General VP | Profile | |
| Philip Ashman | Sr. VP and European Managing Director | Profile | |
| Samer Kaba | Chief Medical Officer | Profile | |
| Jason Werner | Chief Officer | Profile | |
| Charles Myers | NonEx Consultant | Profile | |
| David MD | Chief Specialist | Profile |
About Alimera Sciences Management Performance
The success or failure of an entity such as Alimera Sciences often depends on how effective the management is. Alimera Sciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Alimera management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Alimera management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.36) | (0.38) | |
| Return On Capital Employed | (0.01) | (0.01) | |
| Return On Assets | (0.13) | (0.14) | |
| Return On Equity | (0.44) | (0.41) |
The data published in Alimera Sciences' official financial statements usually reflect Alimera Sciences' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Alimera Sciences. For example, before you start analyzing numbers published by Alimera accountants, it's critical to develop an understanding of what Alimera Sciences' liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Alimera Sciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Alimera Sciences' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Alimera Sciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Alimera Sciences. Please utilize our Beneish M Score to check the likelihood of Alimera Sciences' management manipulating its earnings.
Alimera Sciences Workforce Analysis
Traditionally, organizations such as Alimera Sciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Alimera Sciences within its industry.Alimera Sciences Manpower Efficiency
Return on Alimera Sciences Manpower
| Revenue Per Employee | 524.4K | |
| Revenue Per Executive | 3.5M | |
| Net Loss Per Employee | 130.7K | |
| Net Loss Per Executive | 875.3K | |
| Working Capital Per Employee | 198.1K | |
| Working Capital Per Executive | 1.3M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alimera Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Alimera Stock, please use our How to Invest in Alimera Sciences guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for Alimera Stock analysis
When running Alimera Sciences' price analysis, check to measure Alimera Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alimera Sciences is operating at the current time. Most of Alimera Sciences' value examination focuses on studying past and present price action to predict the probability of Alimera Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alimera Sciences' price. Additionally, you may evaluate how the addition of Alimera Sciences to your portfolios can decrease your overall portfolio volatility.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| CEOs Directory Screen CEOs from public companies around the world | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |
Is Alimera Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alimera Sciences. If investors know Alimera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alimera Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.84) | Revenue Per Share 3.159 | Quarterly Revenue Growth 0.875 | Return On Assets (0.01) | Return On Equity (1.59) |
The market value of Alimera Sciences is measured differently than its book value, which is the value of Alimera that is recorded on the company's balance sheet. Investors also form their own opinion of Alimera Sciences' value that differs from its market value or its book value, called intrinsic value, which is Alimera Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alimera Sciences' market value can be influenced by many factors that don't directly affect Alimera Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alimera Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alimera Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alimera Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.